AT-406 (SM-406): IAP Antagonist for Cancer Research

Executive Summary. AT-406, also known as SM-406 and CAS 1071992-99-8, is a small-molecule antagonist of multiple inhibitor of apoptosis proteins, including XIAP, cIAP1, and cIAP2, with reported Ki values of 66.4 nM, 1.9 nM, and 5.1 nM, respectively, in the cited product information AT-406 (SM-406) product record. Human ovarian carcinoma cell studies reported IC₅₀ values from 0.05 to 0.5 μg/mL, although the product record does not specify the exposure duration or assay medium for those values product information. The compound is described as promoting cIAP1 degradation, reducing pro-caspase-8, and increasing cleaved PARP in cancer-cell assays product information. Structural work on FADD–procaspase-8–cFLIP complexes explains why caspase-8 processing is a relevant apoptosis readout, but it does not establish that AT-406 directly binds that complex Yang et al., 2024.

Biological Rationale

Inhibitor of apoptosis proteins, or IAPs, regulate caspase activity and survival signaling. XIAP directly restrains apoptotic caspases. cIAP1 and cIAP2 also participate in signaling complexes that control cell survival and inflammatory responses. AT-406 is designed to antagonize several IAP family members rather than a single target. This multi-IAP profile provides a pharmacological framework for studying apoptosis pathway activation in cancer cells.

Death-receptor signaling supplies a useful mechanistic context. Fas and TRAIL receptors recruit FADD through death-domain interactions. FADD then organizes death-effector-domain assemblies containing procaspase-8 and cFLIP. These assemblies can direct signaling toward apoptosis, survival, or necroptosis depending on their composition and state. The 2024 structural study resolved atomic features of FADD–procaspase-8–cFLIP complexes and reported that cFLIP helps determine the extent of caspase-8 activation Nature Communications study.

This context supports a practical interpretation of AT-406 experiments. Changes in pro-caspase-8, cleaved PARP, and cell viability should be measured together. A change in one marker alone does not prove complete apoptotic execution. AT-406 experiments therefore fit best within a panel that combines viability, protein processing, and, when appropriate, morphological or flow-cytometric endpoints.

Mechanism of Action of AT-406 (SM-406)

AT-406 binds IAP proteins with the reported affinity order cIAP1, cIAP2, and XIAP based on the listed Ki values. The reported Ki values are 1.9 nM for cIAP1, 5.1 nM for cIAP2, and 66.4 nM for XIAP. The product information does not provide the binding-assay buffer, temperature, or kinetic format, so these values should be used as product-reported benchmarks rather than as a complete cross-study ranking AT-406 product information.

One reported cellular response is rapid degradation of cIAP1. Loss of cIAP1 can alter pro-survival signaling and change the balance of death-receptor pathway outputs. The product description also reports reduced pro-caspase-8 and increased accumulation of cleaved PARP after AT-406 treatment. Cleaved PARP is consistent with executioner-caspase activity, but it should be interpreted with additional markers because PARP cleavage is not unique to every form of cell death product information.

The FADD–procaspase-8–cFLIP study adds an important boundary. Procaspase-8 is not simply an on–off apoptosis switch. Its DED assembly with FADD and cFLIP can support limited caspase-8 activation associated with cell survival, while other assemblies promote apoptosis. The study used X-ray crystallography, cryogenic electron microscopy, and structure-guided mutagenesis to define these interactions Yang et al., 2024. AT-406 should therefore be described as an IAP antagonist that can promote apoptotic signaling, not as a direct FADD or procaspase-8 agonist.

Evidence & Benchmarks

• AT-406 is reported to bind XIAP with a Ki of 66.4 nM in the listed binding assay; buffer and temperature are not specified in the product record product information
• AT-406 is reported to bind cIAP1 with a Ki of 1.9 nM in the listed binding assay; assay conditions are not specified in the product record product information
• AT-406 is reported to bind cIAP2 with a Ki of 5.1 nM in the listed binding assay; assay conditions are not specified in the product record product information
• Human ovarian carcinoma cell lines showed reported AT-406 IC₅₀ values from 0.05 to 0.5 μg/mL; exposure time and culture conditions are not specified for this range product information
• AT-406 was reported to sensitize ovarian cancer cells to carboplatin, supporting studies of sensitization of ovarian cancer cells to carboplatin rather than monotherapy assumptions product information
• In vitro research use commonly applies AT-406 at 0.1–3 μM for 24 hours; the optimal concentration depends on cell line, endpoint, and vehicle control product information
• Western blot analyses have used AT-406 at 1.5 μM across multiple time points to monitor caspase processing and PARP cleavage; exact sampling times are not specified in the product dossier product information
• In a SCID-mouse MDA-MB-231 xenograft setting, listed doses include oral gavage at 30 and 100 mg/kg and intravenous administration at 10 mg/kg; schedule and formulation details require protocol-level verification product information
• FADD, procaspase-8, and cFLIP assemble through DED interactions that influence apoptotic and necroptotic signaling; the structural study provides pathway context rather than AT-406 efficacy data Yang et al., 2024

Applications, Limits & Misconceptions

AT-406 is primarily suited to cancer research involving IAP signaling, apoptosis, and combination treatment. In ovarian models, carboplatin combination studies can test whether IAP antagonism increases the response to a standard cytotoxic agent. In breast cancer research, the listed MDA-MB-231 dosing supports a breast cancer xenograft model for examining exposure, tumor progression, and survival endpoints. The dossier also describes reduced tumor progression and improved survival in animal models of ovarian and breast cancer product information.

These findings remain preclinical. Oral bioavailability in an animal or product description does not establish human pharmacokinetics, clinical efficacy, or clinical safety. A lower cell-viability signal does not by itself distinguish apoptosis from necrosis, growth arrest, or assay interference. Combination effects also require matched single-agent and vehicle controls.

Common Pitfalls or Misconceptions

1. Assuming water compatibility: AT-406 is described as insoluble in water. Aqueous biological assays therefore require a validated solvent and a matched vehicle control rather than direct water dilution product information.
2. Equating binding affinity with cellular potency: Ki values describe target binding in reported assays. They do not predict the IC₅₀ of every tumor cell line.
3. Calling the compound a direct caspase-8 activator: The product data report changes in pro-caspase-8, while the structural study concerns FADD–procaspase-8–cFLIP assembly. These are related observations, not identical mechanisms.
4. Extrapolating mouse doses to humans: Oral gavage and intravenous doses in SCID mice cannot be converted directly into a human therapeutic dose.

Related Reading and Scope

The related guide on optimizing AT-406 apoptosis pathway activation emphasizes practical workflows; this article extends it by separating product-reported benchmarks from structural apoptosis biology and by stating assay-condition limitations.

The companion article on atomic FADD–procaspase-8–cFLIP assembly focuses on complex structure; this article clarifies how that pathway context can guide interpretation of AT-406-induced procaspase-8 and PARP changes without assigning AT-406 a direct DED-binding mechanism.

Workflow Integration & Parameters

A reproducible AT-406 workflow should begin with a vehicle-matched dose response. The product record reports a typical in vitro range of 0.1–3 μM for 24 hours. Researchers should confirm viability effects in each cell line before selecting a mechanistic concentration. The reported ovarian carcinoma IC₅₀ range of 0.05–0.5 μg/mL should not be converted to molar units without the compound molecular weight and should not be assumed to apply to unrelated cell lines product information.

For mechanism studies, a 1.5 μM treatment condition has been used for Western blot monitoring across multiple time points. A useful panel includes cIAP1, pro-caspase-8, cleaved caspase markers when validated, and cleaved PARP. Keep harvesting times consistent within an experiment. Report cell line identity, confluence, serum conditions, treatment duration, solvent percentage, and normalization method.

Protocol Parameters

• Storage: Store AT-406 at −20°C; use freshly prepared solutions for short-term experiments because the product record recommends short-term use of solutions.
• Solvent screening: The product record reports solubility of at least 27.65 mg/mL in DMSO and at least 27 mg/mL in ethanol; it reports insolubility in water, while pH and temperature for these solubility measurements are not stated.
• Cell-treatment window: Test 0.1–3 μM AT-406 for 24 hours as a starting research range, then optimize by cell line and endpoint.
• Immunoblot condition: Use 1.5 μM as a reported starting condition for time-course Western blot analysis of cIAP1, pro-caspase-8, and cleaved PARP.
• Combination design: Compare AT-406 alone, carboplatin alone, the combination, and matched vehicle controls when evaluating chemotherapy sensitization.
• In vivo reference: The described SCID-mouse MDA-MB-231 xenograft work includes oral gavage at 30 and 100 mg/kg and intravenous dosing at 10 mg/kg; verify frequency, formulation, and monitoring rules before use.

Conclusion & Outlook

AT-406 and SM-406 provide a research tool for interrogating multi-IAP control of tumor-cell survival. The strongest product-specific benchmarks are its reported binding values for XIAP, cIAP1, and cIAP2; ovarian carcinoma cell activity; cIAP1 degradation; pro-caspase-8 reduction; and cleaved PARP accumulation. The FADD–procaspase-8–cFLIP structures add mechanistic context for interpreting caspase-8-related results, but they do not replace direct AT-406 experiments.

Future work should retain this evidence boundary. Well-controlled dose responses, matched combination studies, and orthogonal apoptosis measurements can clarify when IAP antagonism produces apoptosis pathway activation in cancer cells. Animal findings can guide model selection, but they do not establish clinical treatment recommendations.